Bioline Rx Ltd - ADR
BLRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.62M
Close$
$-2.52
189.4% downside
Current Fair Value
189.4% downsideOvervalued by 189.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.62 Million |
|---|---|
| Enterprise Value | $19.18 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.29 |
| Beta | 0.62 |
| Outstanding Shares | 4,433,715 |
Return
| Return on Equity | -43.28% |
|---|---|
| Return on Assets | -18.60% |
| Return on Invested Capital | -1.81% |
Valuation & Multiples
| P/E Ratio | -1.28 |
|---|---|
| PEG | 0.85 |
| Price to Sales | 2.82 |
| Price to Book Ratio | 0.71 |
| Enterprise Value to Revenue | 3.21 |
| Enterprise Value to EBIT | -42.16 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.47 |
| Debt to Equity | 0.54 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 27, 2026
EPS Estimate
$-1.04
Average shareholder expectationRevenue Estimate
$343,000
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
$428,500
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 103.45% |
|---|---|
| Total Calls | 10,200▼ 12.07% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.44%▼ 0.72% |
|---|---|
| Total Invested | $45,224▼ 66.66% |
| Investors Holding | 13▼ 2.00% |
ESG Score
No data
About Bioline Rx Ltd
CEO: Philip Serlin